Dr. Arash Ash Alizadeh, MD, PhD

Dr. Alizadeh practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Alizadeh's NPI, 1295824423, was assigned on October 12, 2006. Dr. Alizadeh graduated from Stanford University School Of Medicine in 2003. Dr. Alizadeh's California license number on file is A92354.

Dr. Alizadeh's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Alizadeh's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Alizadeh is also affiliated with Enloe Health. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Alizadeh to 1 more hospital, named with a free account. Dr. Alizadeh's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alizadeh practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Alizadeh's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Alizadeh is board certified in medical oncology by the American Board of Internal Medicine. Dr. Alizadeh has a license on file in California.

Dmand AI lists chronic leukemia and lymphoma among the conditions Dr. Alizadeh treats.

CMS data shows 146 Medicare services from Dr. Alizadeh across 1 procedure code in 2024, all of them office visits, for 70 Medicare patients. Medicare paid $19,260 for them.

CMS counts 70 Medicare patients who saw Dr. Alizadeh in 2024. The largest group is 65 to 74, with 41 patients. 73% of them have high cholesterol, and 53% have high blood pressure. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alizadeh's median patient age at 68, with 43% women.

In 2024, Dr. Alizadeh wrote 29 Medicare Part D claims. 100% of them were for generic drugs. They cover 3 drugs, with $445 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Alizadeh for performance year 2024, reported as part of a group. Dr. Alizadeh accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Alizadeh as offering telehealth.

Dmand AI links 140 papers to Dr. Alizadeh, published from 2000 to 2024. 2015 was the busiest year, with 10. The most frequent topics are Lymphoma, Large B-Cell, Diffuse, Oligonucleotide Array Sequence Analysis and Gene Expression Profiling. Dr. Alizadeh has published most often in Blood. Dr. Alizadeh's most frequent co-authors are Maximilian Diehn, MD, PhD, David Matthew Kurtz, MD and Izidore Lossos, MD.

CMS Open Payments shows 63 general payments to Dr. Alizadeh from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 85% of the total. Gilead Sciences, Inc. paid the most, $26,171.

Dmand AI lists 1 award for Dr. Alizadeh, most recently CMS Stage 1 EHR in 2013.

Dr. Alizadeh graduated from Stanford University School Of Medicine in 2003. Dr. Alizadeh is a member of AACR, ASCO and ASH.

Dr. Alizadeh is in network with 9 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.